Michael Munley to Survival Rate
This is a "connection" page, showing publications Michael Munley has written about Survival Rate.
Connection Strength
0.137
-
Soike MH, McTyre ER, Hughes RT, Farris M, Cramer CK, LeCompte MC, Lanier CM, Ruiz J, Su J, Watabe K, Bourland JD, Munley MT, O'Neill S, Laxton AW, Tatter SB, Chan MD. Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes? J Neurooncol. 2018 Sep; 139(2):461-467.
Score: 0.034
-
Kilburn JM, Lester SC, Lucas JT, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):572-6.
Score: 0.026
-
Loganathan AG, Chan MD, Alphonse N, Peiffer AM, Johnson AJ, McMullen KP, Urbanic JJ, Saconn PA, Bourland JD, Munley MT, Shaw EG, Tatter SB, Ellis TL. Clinical outcomes of brain metastases treated with Gamma Knife radiosurgery with 3.0?T versus 1.5?T MRI-based treatment planning: have we finally optimised detection of occult brain metastases? J Med Imaging Radiat Oncol. 2012 Oct; 56(5):554-60.
Score: 0.023
-
Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, Ekstrand KE, McMullen KP, Munley MT, Shaw EG, Urbanic JJ, Tatter SB. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg. 2011 Jun; 114(6):1585-91.
Score: 0.020
-
Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, Glazier SS, McMullen KP, Munley M, Stieber VW, Tatter SB, Shaw EG. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):208-13.
Score: 0.017
-
Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63.
Score: 0.017